HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
ID: 337273Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337273

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-034.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity under the HEAL Initiative aimed at discovering and validating novel therapeutic targets for safe and effective pain treatment through basic science research. This initiative focuses on identifying targets within various biological systems, including the peripheral and central nervous systems, to develop pain therapies that minimize side effects and reduce addiction potential. The urgency of this initiative is underscored by the ongoing opioid crisis, emphasizing the need for non-addictive pain management alternatives. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and for-profit entities, with funding anticipated for 8-10 awards over a five-year project duration. Interested parties must submit their applications by December 6, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. For more details, visit the full announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-034.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    RFA-NS-22-034-Full-Announcement.html
    RFA-NS-22-034.html
    The Department of Health and Human Services has announced a Funding Opportunity Announcement (FOA) under the HEAL Initiative aimed at discovering and validating novel therapeutic targets for pain treatment through basic science research. Specifically, it focuses on identifying targets within various biological systems—including the peripheral and central nervous systems—that can lead to pain therapies with minimal side effects and low addiction potential. The initiative encourages projects addressing diverse pain conditions, such as chronic pain, migraines, and conditions in underrepresented populations, while emphasizing the need for rigorous target validation to enhance therapeutic development. Funding is available for new and resubmission applications, with an anticipated aim to issue 8-10 awards totaling five years in project duration. Eligible applicants may include higher education institutions, nonprofits, and for-profit organizations, among others. Organizations must meet specific registration and submission requirements to apply. The review process will assess significance, innovation, and approach, as well as the capability of the investigators, ensuring a comprehensive evaluation aligned with NIH priorities. This FOA underscores the urgency of developing non-addictive pain management alternatives amid the ongoing opioid crisis.
    Similar Opportunities
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at developing innovative therapies and technologies for enhanced pain management. This initiative specifically seeks applications from small businesses focused on creating non-addictive pain treatment alternatives, objective pain measurement tools, and new screening methodologies to address the national opioid crisis. With an annual funding projection of up to $8 million for 5-15 awards, eligible applicants must be U.S. small businesses, and the application deadline is set for April 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-006.html.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices," aimed at addressing the opioid epidemic by promoting innovative research into alternative pain management solutions. This initiative seeks interdisciplinary research teams composed of multiple Principal Investigators (PDs/PIs) to explore the mechanisms of action of FDA-approved medical devices designed for pain relief, with the goal of optimizing therapeutic outcomes and enhancing understanding of device-based therapies. With over 25 million Americans suffering from chronic pain, this funding is critical for developing safe and effective pain treatment options that minimize addiction risks. Interested applicants can apply for grants with an award ceiling of $1.5 million, and proposals are due by June 9, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-028.html.
    HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management," aimed at addressing the national opioid public health crisis. This initiative encourages small businesses to develop innovative, non-addictive therapies and technologies for improved pain management, including new medications, pain-assessment devices, and treatment strategies for chronic pain. The funding available includes up to $275,766 for Phase I and $1,838,436 for Phase II grants, with applications due by April 4, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at understanding individual differences in human pain conditions through the R01 grant mechanism. This initiative seeks research proposals that focus on the holistic understanding of pain variability among individuals, emphasizing the collection of clinical and preclinical data to inform personalized pain management strategies. The program is particularly relevant in the context of addressing the ongoing opioid crisis and aims to foster innovative, evidence-based solutions for pain treatment by encouraging multidisciplinary approaches and patient engagement. Approximately $4 million is available to support 3-4 awards, with applications due by February 6, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, aimed at understanding individual differences in human pain conditions through the R01 grant mechanism. This initiative seeks to support research that holistically examines inter-individual differences in pain experiences, focusing on personalized pain management strategies and the collection of clinical and preclinical data. The funding is particularly important for advancing knowledge on the biological and psychosocial factors influencing pain sensitivity and treatment responses, especially in underserved populations. NIH plans to allocate approximately $4 million for 3-4 awards, with each application eligible for up to $650,000 in direct costs over a five-year period. Interested applicants must submit their proposals by February 6, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative for the development of clinical-grade diagnostic and therapeutic devices aimed at treating pain and addressing opioid use disorder (OUD). This grant seeks to support the creation of non-addictive device-based technologies, advancing them from early development to preclinical stages suitable for FDA approval, with a focus on demonstrating treatment efficacy through credible neural targets. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, for-profit entities, and tribal governments, with funding available for up to three years and a maximum budget of $750,000 annually. Interested parties should note that the application deadline is June 17, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.